ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

2 years ago

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated…

World Orphan Drug Alliance Expands to China, Israel, and Greece, Cyprus, and Malta

2 years ago

Greater China region, Israel, and Greece, Cyprus and Malta are now also covered by the alliance. With the addition of…

BioVie Announces Registration Details for “BioVie Day” Webinar

2 years ago

Virtual Webinar to be held March 23, 2023, at 10:00am Eastern TimeCARSON CITY, Nev., March 14, 2023 (GLOBE NEWSWIRE) --…

More Than Rehab’s Medical Director, Dr. Michael Jones, now Board-Certified in Addiction Medicine

2 years ago

BRYAN, Texas, March 14, 2023 (GLOBE NEWSWIRE) -- More Than Rehab is excited to announce that their Medical Director, Dr.…

Gradalis Announces Publication in Clinical Cancer Research Featuring Positive Results from a Study Evaluating Vigil® in Combination Therapy for Patients with Recurrent Ewing’s Sarcoma

2 years ago

-Pilot study in Ewing's Sarcoma supports the therapeutic potential of Vigil in multiple solid tumor types- -Circulating tumor DNA levels,…

STRATA Skin Sciences to Report Fourth Quarter 2022 Financial Results on March 28, 2023

2 years ago

HORSHAM, Pa., March 14, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to…

Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer

2 years ago

Media Release Integrated Phase II/III trial design incorporates feedback from the FDA and EMA and will help inform a BLA…

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results

2 years ago

Initiation of APEX Part 2 planned for mid-2023Updated clinical data from Phase 3 PEAK lead-in in GIST patients expected 1H23Initial…

Culture Biosciences Focuses Technology and Service Platform on Biologics

2 years ago

Intelligent upstream bioprocess development for therapeutics using an integrated platform of cloud-based software, single-use bioreactors, simulation tools, and process development…

Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs

2 years ago

PVTX-321 and PVTX-405 Achieve Development Candidate NominationNEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- Proteovant Therapeutics, a Roivant Sciences (Nasdaq: ROIV) company…